美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Veraxa Biotech Holding AG

1.12

-0.0800-6.67%

成交量：10.97万

成交额：12.92万

市值：1.58亿

市盈率：5.23

高：1.21

开：1.19

低：1.11

收：1.20

52周最高：27.36

52周最低：1.04

股本：1.41亿

流通股本：3,676.75万

量比：1.05

换手率：0.30%

股息：- -

股息率：- -

每股收益(TTM):0.2142

每股收益(LYR):-5.8037

净资产收益率：-871.42%

总资产收益率：-49.99%

市净率：-8.37

市盈率(LYR):-0.19

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Veraxa Biotech公布将FDA认可的人体相关模型纳入研发战略的实施概况

Veraxa Biotech AG：体外概念验证研究取得积极成果，有望融合双方技术与专长开创全新AOC疗法

Veraxa Biotech与Secarna Pharmaceuticals达成抗体寡核苷酸偶联联盟研究里程碑

Veraxa Biotech Holding AG强化专利布局，筑牢核心技术平台与产品管线护城河

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/VRXA"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.12,"timestamp":1791474223022,"preClose":1.2,"halted":0,"volume":109747,"delay":0,"changeRate":-0.06666666666666654,"floatShares":36767500,"shares":141407813,"eps":0.2142,"marketStatus":"交易中","change":-0.08,"latestTime":"10-08 11:44:01 EDT","open":1.19,"high":1.21,"low":1.11,"amount":129171.3849228,"amplitude":0.083333,"askPrice":1.2,"askSize":280,"bidPrice":1.1,"bidSize":1010,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.2,"preHourTrading":{"tag":"盘前","latestPrice":1.18,"preClose":1.2,"latestTime":"09:29 EDT","volume":3148,"amount":3746.123148,"timestamp":1791466141064,"change":-0.02,"changeRate":-0.016667,"amplitude":0.108167},"postHourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.2,"latestTime":"19:37 EDT","volume":23375,"amount":27177.388,"timestamp":1791416255328,"change":0.02,"changeRate":0.016667,"amplitude":0.08275},"volumeRatio":1.045117},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":36767500,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":1.045117,"shares":141407813,"dividePrice":0,"high":1.21,"amplitude":0.083333,"preClose":1.2,"low":1.11,"week52Low":1.04,"pbRate":"-8.37","psRate":"5632.80","week52High":27.36,"institutionHeld":0,"latestPrice":1.12,"committee":0.565891,"eps":0.2142,"divideRate":0,"volume":109747,"delay":0,"ttmEps":0.2142,"open":1.19,"prevYearClose":18.65,"prevWeekClose":1.13,"prevMonthClose":1.25,"prevQuarterClose":1.25,"fiveDayClose":1.19,"twentyDayClose":1.65,"sixtyDayClose":2.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-10-07","current":5.602241,"percent":0.69697,"low":-3.022108,"twenty":-2.642567,"median":-2.3968,"eighty":-1.311559,"high":-0.413162,"avg":-2.05439,"sd":0.748253,"marketCap":152720438},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-04","current":-2.622384,"twenty":-1.391748,"median":-1.265172,"eighty":-0.552029,"marketCap":216353953},{"date":"2026-09-11","current":-2.842124,"twenty":-2.738773,"median":-1.34261,"eighty":-1.03732,"marketCap":233322891},{"date":"2026-09-18","current":-2.57236,"twenty":-2.751957,"median":-2.365287,"eighty":-1.181392,"marketCap":207869485},{"date":"2026-09-25","current":-2.481882,"twenty":-2.738773,"median":-2.472656,"eighty":-1.249249,"marketCap":199385016},{"date":"2026-10-02","current":-2.09825,"twenty":-2.642883,"median":-2.446678,"eighty":-1.281094,"marketCap":168275297},{"date":"2026-10-07","current":-1.911149,"twenty":-2.642567,"median":-2.3968,"eighty":-1.311559,"marketCap":152720438}],"updateTime":1791457650593},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1150146544","title":"Veraxa Biotech公布将FDA认可的人体相关模型纳入研发战略的实施概况","url":"https://stock-news.laohu8.com/highlight/detail?id=1150146544","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150146544?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 19:01","pubTimestamp":1791370869,"startTime":"0","endTime":"0","summary":"Veraxa Biotech公布将FDA认可的人体相关模型纳入研发战略的实施概况","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172247840","title":"Veraxa Biotech AG：体外概念验证研究取得积极成果，有望融合双方技术与专长开创全新AOC疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1172247840","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172247840?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 19:44","pubTimestamp":1787571855,"startTime":"0","endTime":"0","summary":"Veraxa Biotech AG近日宣布，一项成功的体外概念验证研究初步显示出令人振奋的潜力——通过整合双方的尖端技术与深厚专业知识，有望催生新一代抗体偶联物的诞生。由此产生的协同效应，或许正是解锁AOC药物更广阔应用空间的关键钥匙。Veraxa Biotech AG方面对此成果表示高度认可，并认为这是公司发展战略中的一个重要里程碑。借助此次合作所积累的经验和数据，后续的研发管线有望得到显著充实和加速。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156560832","title":"Veraxa Biotech与Secarna Pharmaceuticals达成抗体寡核苷酸偶联联盟研究里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1156560832","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156560832?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 19:42","pubTimestamp":1787571733,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG及其合作伙伴Secarna Pharmaceuticals，在抗体寡核苷酸偶联物联盟框架下，成功跨越了一项关键研究里程碑。通过将抗体的靶向特异性与寡核苷酸的治疗潜力相结合，该联盟正致力于开发新一代精准医疗方案。双方团队对此次合作成果表示高度认可，并强调这一里程碑的达成，凝聚了跨学科研究的智慧与不懈努力。展望未来，Veraxa与Secarna将继续深化协作，加速推进项目向临床前及临床阶段转化，以期为患者带来更具变革性的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178040350","title":"Veraxa Biotech Holding AG强化专利布局，筑牢核心技术平台与产品管线护城河","url":"https://stock-news.laohu8.com/highlight/detail?id=1178040350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178040350?lang=zh_cn&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322874,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正全力扩充其专利组合，旨在为公司的核心技术平台与候选产品构建起坚实的知识产权堡垒。这一举措，不仅彰显了企业对创新成果的深度保护，更预示着其在生物科技领域长期战略布局的进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VRXA\",params:#limit:6,delay:false,,,undefined,":[]}}